Diploma (LON:DPLM – Get Free Report) had its price objective boosted by equities researchers at JPMorgan Chase & Co. from GBX 4,370 ($53.49) to GBX 4,420 ($54.10) in a note issued to investors on Tuesday, Marketbeat.com reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 2.84% from the company’s current price.
Several other equities research analysts also recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 5,100 ($62.42) price objective on shares of Diploma in a report on Friday, November 22nd. Shore Capital downgraded Diploma to a “hold” rating in a report on Tuesday, November 19th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Diploma currently has a consensus rating of “Moderate Buy” and an average target price of GBX 4,567.50 ($55.91).
Get Our Latest Stock Report on Diploma
Diploma Trading Up 5.3 %
Insider Activity at Diploma
In related news, insider Chris Davies purchased 3,917 shares of the stock in a transaction dated Friday, December 20th. The shares were acquired at an average cost of GBX 4,280 ($52.39) per share, with a total value of £167,647.60 ($205,199.02). Also, insider Johnny Thomson sold 26,794 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of GBX 4,536 ($55.52), for a total transaction of £1,215,375.84 ($1,487,608.13). 0.52% of the stock is currently owned by insiders.
About Diploma
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Stories
- Five stocks we like better than Diploma
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- How to Use High Beta Stocks to Maximize Your Investing Profits
- How Do Stock Buybacks Affect Shareholders?
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.